
Opinion|Videos|February 22, 2024
Key Data from CAPItello-291 in HR+ Breast Cancer
Hope Rugo, MD, reviews key data from CAPItello-291 on capivasertib in patients with HR+ breast cancer, highlighting progression-free survival and overall survival.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5




































